Synonyms: compound 4 [WO2019218987A1] [2] | D-0316 | D0316 | Surmana®
befotertinib is an approved drug (China NMPA (2023))
Compound class:
Synthetic organic
Comment: Befotertinib (D-0316) is an third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that was developed as a treatment for non-small cell lung cancer (NSCLC) [2].
|
|
Bioactivity Comments |
Befotertinib inhibits proliferation of NSCLC cells with IC50 values of 543 nM (WT EGFR) and 15.7 (EGFR with double mutant L858R/T790M) [3]. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|